Trial · NCT04385277
Adverse events54
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 54
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 2 | 40 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 7 | 40 | |
| other | Sinus tachycardia | Cardiac disorders | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 1 | 40 | |
| other | Abdominal pain | Gastrointestinal disorders | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 1 | 40 | |
| other | Dental caries | Gastrointestinal disorders | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 1 | 40 | |
| other | Diarrhea | Gastrointestinal disorders | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 4 | 40 | |
| other | Gastrointestinal pain | Gastrointestinal disorders | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 1 | 40 | |
| other | Mucositis oral | Gastrointestinal disorders | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 1 | 40 | |
| other | Nausea | Gastrointestinal disorders | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 1 | 40 | |
| other | Vomiting | Gastrointestinal disorders | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 2 | 40 | |
| other | Fever | General disorders | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 17 | 40 | |
| other | Pain | General disorders | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 12 | 40 | |
| other | Anaphylaxis | Immune system disorders | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 1 | 40 | |
| other | Enterocolitis infectious | Infections and infestations | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 4 | 40 | |
| other | Infections and infestations - Other, specify | Infections and infestations | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 4 | 40 | |
| other | Otitis media | Infections and infestations | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 1 | 40 | |
| other | Sepsis | Infections and infestations | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 7 | 40 | |
| other | Upper respiratory infection | Infections and infestations | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 2 | 40 | |
| other | Infusion related reaction | Injury, poisoning and procedural complications | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 3 | 40 | |
| other | Alanine aminotransferase increased | Investigations | Treatment (Temozolomide, Irinotecan, Dinutuximab) | 7 | 40 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04385277/events